Sigyn Therapeutics annual shares outstanding
2014
2015
2018
2019
2020
2021
2022
2023
2024
Sigyn Therapeutics Shares Outstanding History (SIGY)
Sigyn Therapeutics reported 1.6M shares outstanding at the end of fiscal 2024.
View full Sigyn Therapeutics company overviewSigyn Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | 1.6M | 316,962 | +24.60% |
| 2023 | 2023-12-31 | 1.3M | −41.4M | −96.98% |
| 2022 | 2023-03-31 | 42.7M | 5.4M | +14.53% |
| 2021 | 2021-12-31 | 37.3M | 2.1M | +5.95% |
| 2020 | 2020-12-31 | 35.2M | 34.7M | +6940.30% |
| 2019 | 2019-12-31 | 500,000 | −80.8M | −99.38% |
| 2018 | 2018-12-31 | 81.3M | 46.9M | +136.79% |
| 2015 | 2015-12-31 | 34.3M | 18.3M | +114.52% |
| 2014 | 2014-12-31 | 16.0M | — | — |
Sigyn Therapeutics quarterly shares outstanding
Q4.14
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
As of Dec 31, 2017
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
As of Aug 10, 2020
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q3.22
Q4.22
Q1.23
Q2.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | 1.6M | 184,699 | +13.00% |
| Q2 2025 | 2025-06-30 | 1.6M | 341,724 | +27.04% |
| Q1 2025 | 2025-03-31 | 1.6M | 380,550 | +31.07% |
| Q4 2024 | 2024-12-31 | 1.6M | 316,962 | +24.60% |
| Q3 2024 | 2024-09-30 | 1.4M | −42.8M | −96.79% |
| Q2 2024 | 2024-06-30 | 1.3M | −43.0M | −97.14% |
| Q1 2024 | 2024-03-31 | 1.2M | −41.6M | −97.14% |
| Q4 2023 | 2023-12-31 | 1.3M | −37.0M | −96.63% |
| Q2 2023 | 2023-09-30 | 44.2M | 6.9M | +18.61% |
| Q1 2023 | 2023-06-30 | 44.2M | 6.9M | +18.60% |
| Q4 2022 | 2023-03-31 | 42.8M | 5.5M | +14.77% |
| Q3 2022 · Dec 31 | 2022-12-31 | 38.3M | 968,010 | +2.60% |
| Q3 2022 · Sep 30 | 2022-09-30 | 37.3M | 567,010 | +1.54% |
| Q2 2022 | 2022-06-30 | 37.3M | 671,157 | +1.83% |
| Q1 2022 | 2022-03-31 | 37.3M | 2.0M | +5.81% |
| Q4 2021 | 2021-12-31 | 37.3M | 2.1M | +5.95% |
| Q3 2021 | 2021-09-30 | 36.7M | 36.1M | +5649.49% |
| Q2 2021 | 2021-06-30 | 36.6M | 36.6M | +24416337.33% |
| Q1 2021 | 2021-03-31 | 35.2M | −60.5M | −63.20% |
| Q4 2020 | 2020-12-31 | 35.2M | −57.2M | −61.92% |
| Q3 2020 | 2020-09-30 | 638,818 | −80.6M | −99.21% |
| As of Aug 10, 2020 | 2020-08-10 | 150 | −81.3M | −100.00% |
| Q2 2020 | 2020-06-30 | 95.8M | 14.5M | +17.84% |
| Q1 2020 | 2020-03-31 | 92.4M | 11.2M | +13.74% |
| Q4 2019 | 2019-12-31 | 81.3M | 0 | 0.00% |
| Q3 2019 | 2019-09-30 | 81.3M | 10.7M | +15.08% |
| Q2 2019 | 2019-06-30 | 81.3M | 18.4M | +29.37% |
| Q1 2019 | 2019-03-31 | 81.3M | 21.8M | +36.58% |
| Q4 2018 | 2018-12-31 | 81.3M | 28.0M | +52.55% |
| Q3 2018 | 2018-09-30 | 70.6M | 36.1M | +104.81% |
| Q2 2018 | 2018-06-30 | 62.8M | 28.4M | +82.63% |
| Q1 2018 | 2018-03-31 | 59.5M | 25.2M | +73.37% |
| As of Dec 31, 2017 | 2017-12-31 | 53.3M | 19.0M | +55.22% |
| Q3 2016 | 2016-09-30 | 34.5M | 4.6M | +15.50% |
| Q2 2016 | 2016-06-30 | 34.4M | 18.4M | +114.98% |
| Q1 2016 | 2016-03-31 | 34.3M | — | — |
| Q4 2015 | 2015-12-31 | 34.3M | — | — |
| Q3 2015 | 2015-09-30 | 29.9M | — | — |
| Q4 2014 | 2014-12-31 | 16.0M | — | — |
Sigyn Therapeutics shares outstanding trends
Over the last five reported fiscal years, Sigyn Therapeutics's shares outstanding moved from 500,000 to 1.6M, a change of 1.1M. The latest reported quarter, Q3 2025, shows 1.6M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sigyn Therapeutics filings at SEC.gov ↗